Real-life comparison of efficacy and safety profiles of two prolonged-release tacrolimus formulations in de novo kidney transplant recipients: 24 months of follow-up.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
02
2022
accepted:
23
11
2022
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Calcineurin inhibitors constitute a cornerstone of immunosuppressive therapy in kidney transplant recipients. There are two main formulations of tacrolimus (Tac) which exhibit a prolonged-release mode of action: Advagraf® (MR-4) and Envarsus® (LCPT). However, they are not bioequivalent. Data comparing both once-daily prolonged-release formulations of Tac are insufficient. The aim of the study was to compare safety and efficacy profiles of once-daily LCPT and MR-4 formulations of tacrolimus in adult kidney transplant recipients. An observational, cohort single-center study was performed. One hundred fifteen kidney transplant recipients transplanted between 2016 and 2019 were enrolled to the study (59 vs 56, Envarsus® vs Advagraf®, respectively). Safety and efficacy profiles were assessed. Patient and graft survival at 12 and 24 months did not differ between the groups. There were no significant differences in serum creatinine at any timepoint. C/D ratio in the LCPT group was significantly higher at 12 and 24 months. Sepsis occurrence was more frequent in MR-4 group at 12 months. Both prolonged-release formulations of tacrolimus are safe and effective in immunosuppressive therapy in kidney transplant recipients.
Identifiants
pubmed: 36662740
doi: 10.1371/journal.pone.0278894
pii: PONE-D-22-02919
pmc: PMC9858018
doi:
Substances chimiques
Tacrolimus
WM0HAQ4WNM
Immunosuppressive Agents
0
Delayed-Action Preparations
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0278894Informations de copyright
Copyright: © 2023 Czarnecka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Kidney J. 2020 Jun 22;13(4):693-709
pubmed: 32897277
J Clin Med. 2019 Oct 02;8(10):
pubmed: 31581670
Clin Transplant. 2020 Jan;34(1):e13767
pubmed: 31815310
Transplantation. 2010 Jan 15;89(1):1-14
pubmed: 20061913
Transplantation. 2016 Aug;100(8):1723-31
pubmed: 27306529
Adv Ther. 2019 Feb;36(2):462-477
pubmed: 30552587
PLoS One. 2014 Oct 23;9(10):e111128
pubmed: 25340655
Transplantation. 2014 Dec 27;98(12):1310-5
pubmed: 24879384
Diabetes Care. 2002 Mar;25(3):583-92
pubmed: 11874952
Transplantation. 2013 Jul 27;96(2):198-204
pubmed: 23792649
Clin Ther. 2002 Mar;24(3):330-50; discussion 329
pubmed: 11952020
Am J Transplant. 2014 Dec;14(12):2796-806
pubmed: 25278376
Immunopharmacology. 2000 May;47(2-3):63-83
pubmed: 10878284
Am J Transplant. 2014 Feb;14(2):272-83
pubmed: 24472190
Am J Transplant. 2012 May;12(5):1157-67
pubmed: 22429309
Am J Transplant. 2010 Dec;10(12):2632-43
pubmed: 20840480
Transplantation. 2013 Feb 15;95(3):410-7
pubmed: 23380861
Am J Transplant. 2017 Feb;17(2):432-442
pubmed: 27340950
Am J Transplant. 2019 Oct;19(10):2805-2813
pubmed: 30859672
Clin Transplant. 2015 Sep;29(9):796-805
pubmed: 26113208